Phaseline

Companies › Autolus

Autolus: clinical trials, targets and expected readouts

1 active drug program in 7 registered trials: 4 Phase 1, 3 Phase 2; Neurology, Immunology, Oncology; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Obecabtagene Autoleucel
B-lymphocyte antigen CD19 binding agent
CD19Phase 2Lupus Nephritis; Systemic Lupus Erythematosus; Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia; Progressive Multiple Sclerosis …Sep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06333483Obecabtagene AutoleucelPhase 1Systemic Lupus ErythematosusImmunologySep 2027
NCT06173518Obecabtagene AutoleucelPhase 1Relapsed or Refractory B Cell Acute Lymphoblastic LeukemiaOncologyNov 2027
NCT07053059Obecabtagene AutoleucelPhase 2Acute Lymphocytic Leukemia (ALL)OncologyMay 2028
NCT07053800Obecabtagene AutoleucelPhase 2Lupus NephritisImmunologyAug 2028
NCT07400029Obecabtagene AutoleucelPhase 2Acute Lymphoblastic LeukemiaOncologyFeb 2029
NCT04404660Obecabtagene AutoleucelPhase 1Relapsed or Refractory B Cell Acute Lymphoblastic LeukemiaOncologyJun 2029
NCT07139743Obecabtagene AutoleucelPhase 1Progressive Multiple SclerosisNeurologyAug 2029

From the company's SEC filings

Cash and short-term investments of $202m on 2026-06-30; operating cash outflow about $183m a year; runway about 13 months at that burn, to Aug 2027; 0 of 3 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

CD19 (1)

Companies with the same targets

Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech Allogene Therapeutics Miltenyi Biomedicine Amgen AstraZeneca Beijing Yongtai Ruike Biotechnology Company Shanghai Ming Ju Biotechnology iCell Gene Therapeutics

Companies built like this

Shanghai Ming Ju Biotechnology Kyverna Therapeutics Beijing Yongtai Ruike Biotechnology Company Juventas Cell Therapy Turn Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.